Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Cognitive Benefit of Rivastigmine in Parkinson’s Disease Dementia with Orthostatic Hypotension
    ABSTRACT & COMMENTARY

    Cognitive Benefit of Rivastigmine in Parkinson’s Disease Dementia with Orthostatic Hypotension

    February 1, 2021
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

    Related Articles

    Cognitive Benefit of Rivastigmine in Parkinson’s Disease Dementia with Orthostatic Hypotension

    Fludrocortisone for Orthostatic Hypotension Associated With Parkinson’s Disease

    Fludrocortisone for Orthostatic Hypotension Associated with Parkinson’s Disease

    Related Products

    Fludrocortisone for Orthostatic Hypotension Associated With Parkinson’s Disease

    Does Rivastigmine Prevent Falls in Parkinson’s Disease?

    Keywords

    treatment

    Dementia

    cognitive

    rivastigmine

    orthostatic

    By Lynda Nwabuobi, MD

    Assistant Professor of Clinical Neurology, Assistant Attending Neurologist, New York Presbyterian/Weill Cornell Medical College

    SYNOPSIS: Individuals with Parkinson’s disease dementia and orthostatic hypotension (OH) have more robust cognitive improvement from rivastigmine compared to those without OH. This greater response possibly is mediated by the anti-OH effect of rivastigmine.

    SOURCE: Espay AJ, Marsili L, Mahajan A, et al. Rivastigmine in Parkinson’s disease dementia with orthostatic hypotension. Ann Neurol 2021;89:91-98.

    Orthostatic hypotension (OH) is a common nonmotor symptom in Parkinson’s disease (PD), with an overall prevalence of 30%, which increases to 65% as the disease progresses. Untreated, it can independently contribute to cognitive impairment in PD individuals, presumably as the result of a reduction in cerebral perfusion pressure. In individuals with Parkinson’s disease dementia (PDD), the presence of untreated OH could negatively affect the efficacy of cholinesterase inhibitors used to treat PDD. Rivastigmine is approved for the treatment of cognitive impairment in people with PDD. Using available clinical trial datasets, the authors tested the hypothesis that the cognitive effect of rivastigmine is reduced in patients with PDD with OH compared to those without OH.

    A post-hoc analysis was performed on three Novartis-sponsored studies of rivastigmine in PDD in which orthostatic blood pressure measurements were recorded: a 24-week randomized, double-blind, placebo-controlled trial of patients with PDD at least two years after diagnosis; a 24-week open-label extension (a total of 48 weeks) in the same population; and a 76-week trial comparing the rivastigmine capsule vs. the transdermal patch. The main outcome was change from baseline in the Alzheimer’s Disease Assessment Scale–Cognitive subscale (ADAS-Cog) in patients with OH vs. patients without OH treated with rivastigmine compared to placebo. A secondary endpoint was change in Mini-Mental State Examination (MMSE) from baseline. The 76-week study used the Mattis Dementia Rating Scale (MDRS) as the outcome measure. The 24-week study was used for the main analysis because it was the only study with a placebo comparator. Statistical analysis included analysis of covariance (ANCOVA) model, with 95% confidence intervals for the difference between the treatment groups; P values were provided without adjustment for multiple comparisons.

    In the rivastigmine vs. placebo study, the mean maintenance daily dose of rivastigmine for the 10 weeks preceding the study endpoint at week 24 was 8.7 mg (standard deviation [SD] = 3.4 mg); 9.8% of all OH patients were receiving OH treatment. There was a larger improvement in ADAS-Cog in the OH group at 24 weeks (5.6 ± 1.2 vs. 1.9 ± 0.9; P = 0.0165). MMSE also was significantly improved by rivastigmine compared to placebo, but only in patients with OH (2.2 ± 4.7 vs. -0.7 ± 3.9; P < 0.001). At 48 weeks, with both groups on rivastigmine, the favorable effect of rivastigmine on ADAS-Cog in the OH group was attenuated (3.2 ± 2.1 vs. -1.1 ± 1.1; P = 0.0741).

    In the rivastigmine patch vs. capsule study, the daily dose during the maintenance period ranged from 8.80 mg/day to 8.87 mg/day in patients who received the rivastigmine capsule and from 9.20 cm2 to 9.40 cm2 in patients who received the rivastigmine patch (10 cm2 patch releases 9.5 mg/24 hours). At week 76, the change in MDRS was significantly greater for OH patients compared to individuals without OH, but only for those on rivastigmine capsules (10.6 ± 2.9 vs. -1.5 ± 3.0 on transdermal patch; P = 0.031).

    At the end of the 24-week study, the prevalence of OH among the patients who had OH at baseline was reduced to 28.3% in the rivastigmine group and 44.6% in the placebo group. Of the OH-negative patients, 5% converted to OH in the placebo arm compared to 1.7% in the rivastigmine arm. Syncope was more common in the OH placebo group (9.2%) compared to the OH rivastigmine group, which had no cases of syncope.

    COMMENTARY

    Contrary to their hypothesis, the authors found that rivastigmine had a greater cognitive benefit in PDD patients with OH compared to individuals without OH, despite similar severity of cognitive impairment at baseline. Also, it appeared to have a protective effect of reducing OH, given the lower prevalence at the end of the 24-week study and no episodes of syncope in the rivastigmine group. This paradoxical effect may be explained by an anti-OH effect of the medication, as seen in a related ganglionic acetylcholinesterase inhibitor, pyridostigmine, which has been shown to reduce OH. These findings suggest a potential role of rivastigmine as an adjunct treatment strategy for OH in PD. An interesting subanalysis would be to investigate whether treatment with OH medications contributed to the amount of cognitive improvement seen in OH patients. If this is the case, it brings up the question whether all PDD patients should be on OH medications to boost the effectiveness of cholinesterase inhibitors.

    Post a comment to this article

    Report Abusive Comment

    www.reliasmedia.com

    Neurology Alert

    View PDF
    Neurology Alert (Vol. 40, No. 6) - February 2021
    February 1, 2021

    Table Of Contents

    Focused Ultrasound in Parkinson’s Disease: Going Beyond Tremor

    Deficits in Neurotransmitters and Behavioral Disturbances in Frontotemporal Lobar Degeneration

    Cognitive Benefit of Rivastigmine in Parkinson’s Disease Dementia with Orthostatic Hypotension

    Prednisone vs. Placebo in Short-Term Prevention of Episodic Cluster Headaches

    Clinical and Genetic Characterizations to Diagnose Sarcoglycanopathies

    Begin Test

    Buy this Issue/Course

    Financial Disclosure: Dr. Kaplitt, author, reports he receives grant support from the Focused Ultrasound Foundation. Dr. Rubin, author, reports he is a consultant for Merck Sharpe & Dohme Corp. All of the relevant financial relationships listed for these individuals have been mitigated. None of the remaining authors or planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • My Subscription
      • Subscribe Now
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421 x 2

    International +1-404-262-5476 x 2

    Accounts Receivable

    1-800-688-2421 x 3
    ReliasMedia_AR@reliasmedia.com

    Sales

    1-800-688-2421 x 1

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2022 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing